What one share of Veradermics holds
We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the “Company,” “we,” “us,” or “our”, focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions.
Veradermics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$6.50 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.88 |
| Cash and investments | $7.64 |
| Book value | $19.47 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$37.05 | $0.00 | −$32.14 | — | −$65.79 |
| 2025 | — | −$111.91 | $0.03 | −$96.14 | — | −$161.40 |
Common questions about Veradermics
How much does one share of Veradermics earn?
Over the last 12 months, Veradermics lost $6.50 for each share.
Does Veradermics pay a dividend?
Veradermics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Veradermics’s book value per share?
Veradermics’s book value is $19.47 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Veradermics have?
Each share of Veradermics has $7.64 of cash and investments, as of June 30, 2026.
What is Veradermics’s free cash flow per share?
−$4.88 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.